{"id":613628,"date":"2022-08-26T17:42:01","date_gmt":"2022-08-26T17:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=613628"},"modified":"2022-08-26T17:42:01","modified_gmt":"2022-08-26T17:42:01","slug":"esophageal-squamous-cell-carcinoma-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/esophageal-squamous-cell-carcinoma-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies_613628.html","title":{"rendered":"Esophageal Squamous Cell Carcinoma Pipeline Assessment &#8211; FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1661499000.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Esophageal Squamous Cell Carcinoma Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies\" src=\"https:\/\/www.abnewswire.com\/uploads\/1661499000.jpeg\" alt=\"Esophageal Squamous Cell Carcinoma Pipeline Assessment - FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, Growth Prospects, and Key Companies\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Esophageal Squamous Cell Carcinoma Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">The most common types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. These two forms of esophageal cancer tend to develop in different parts of the esophagus and are driven by different genetic changes.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\"><strong>Esophageal Squamous Cell Carcinoma Pipeline Insight, 2022<\/strong><\/a>&rdquo; report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Esophageal Squamous Cell Carcinoma Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Esophageal Squamous Cell Carcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&rsquo;s Report covers around 50+ products under different phases of clinical development like<\/strong><\/p>\n<p style=\"text-align: justify;\">&bull; Late-stage products (Phase III)<\/p>\n<p style=\"text-align: justify;\">&bull; Mid-stage products (Phase II)<\/p>\n<p style=\"text-align: justify;\">&bull; Early-stage product (Phase I)<\/p>\n<p style=\"text-align: justify;\">&bull; Pre-clinical and Discovery stage candidates<\/p>\n<p style=\"text-align: justify;\">&bull; Discontinued &amp; Inactive candidates<\/p>\n<p style=\"text-align: justify;\">&bull; Route of Administration<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Esophageal Squamous Cell Carcinoma &ndash; Emerging Drugs Under Different Phases of Clinical Development Include:<\/strong><\/p>\n<p style=\"text-align: justify;\">&bull; Tocilizumab: BeiGene<\/p>\n<p style=\"text-align: justify;\">&bull; Serplulimab: Shanghai Henlius Biotech<\/p>\n<p style=\"text-align: justify;\">And Many Others<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Further product details are provided in the report. Download the report to learn more about the emerging therapies at:&nbsp; <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/esophageal-squamous-cell-carcinoma-pipeline-insight<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Esophageal Squamous Cell Carcinoma Pipeline Analysis<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Squamous Cell Carcinoma with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the&nbsp; treatment of Esophageal Squamous Cell Carcinoma Treatment.<\/li>\n<li>Treatment of Esophageal Squamous Cell Carcinoma key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Treatment of Esophageal Squamous Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of theTreatment of Esophageal Squamous Cell Carcinoma Drugs &nbsp;&nbsp;market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report &ndash; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/esophageal-squamous-cell-carcinoma-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/esophageal-squamous-cell-carcinoma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies in the Esophageal Squamous Cell Carcinoma Therapeutics Market include:<\/strong><\/p>\n<p style=\"text-align: justify;\">BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, AstraZeneca, Servier, Ipsen, Shire, Sanofi, Eli Lilly and Company, Seagen IncNovartis Pharmaceuticals, Bayer, Eisai Inc, Exelixis, Symphogen AS, Jiangsu HengRui Medicine Co.Ltd, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co. Ltd, Sinocelltech LtdJacobio Pharmaceuticals Co.Ltd, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co.Ltd, Rapa Therapeutics LLC, Incyte Corporation and others.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report &ndash; <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/esophageal-squamous-cell-carcinoma-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/esophageal-squamous-cell-carcinoma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3.&nbsp; Esophageal Squamous Cell Carcinoma Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">4.&nbsp; Esophageal Squamous Cell Carcinoma &ndash; DelveInsight&rsquo;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6.&nbsp; Esophageal Squamous Cell Carcinoma Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7.&nbsp; Esophageal Squamous Cell Carcinoma Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8.&nbsp; Esophageal Squamous Cell Carcinoma Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9.&nbsp; Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Esophageal Squamous Cell Carcinoma Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13.&nbsp; Esophageal Squamous Cell Carcinoma Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Key Companies in the&nbsp; Esophageal Squamous Cell Carcinoma&nbsp; Market<\/p>\n<p style=\"text-align: justify;\">15. Key Products in the Esophageal Squamous Cell Carcinoma Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Esophageal Squamous Cell Carcinoma Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Esophageal Squamous Cell Carcinoma Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Esophageal Squamous Cell Carcinoma Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\">*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Trending Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/age-related-vision-dysfunction-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>Age related vision dysfunction market<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">(Albany, US) DelveInsight&rsquo;s&nbsp;<strong>&ldquo;Age related vision dysfunction Market Insights, Epidemiology, and Market Forecast-2032&Prime;<\/strong>&nbsp;report offers an in-depth understanding of the Age related vision dysfunction, historical and forecasted epidemiology as well as the Age related vision dysfunction market trends in the United States, EU5 (Germany, Spain, Italy,France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=esophageal-squamous-cell-carcinoma-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/esophageal-squamous-cell-carcinoma-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/esophageal-squamous-cell-carcinoma-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/esophageal-squamous-cell-carcinoma-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=esophageal-squamous-cell-carcinoma-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Esophageal Squamous Cell Carcinoma Pipeline The most common types of esophageal cancer are adenocarcinoma and squamous cell carcinoma. These two forms of esophageal cancer tend to develop in different parts of the esophagus and are driven by different genetic changes. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/esophageal-squamous-cell-carcinoma-pipeline-assessment-fda-ema-and-pmda-approvals-emerging-drugs-clinical-trials-therapeutic-analysis-growth-prospects-and-key-companies_613628.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,406,413,404],"tags":[],"class_list":["post-613628","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/613628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=613628"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/613628\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=613628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=613628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=613628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}